GlassScriptPhysician profile
Venus Mercado Kell
NPI 1265196562
$5,761.48
in general payments reported to CMS, 2019-2025
51 companies · $739 in 2025
The $739 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $123 · 2023: $3,252 · 2024: $1,648 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,638.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $813.59 | 2023-2025 | |
| Ucb, INC. | $542.12 | 2023-2024 | Briviact, Nayzilam, Rystiggo |
| Neurocrine Biosciences, INC. | $338.17 | 2022-2024 | Ingrezza, Ongentys |
| Abiomed | $328.18 | 2024-2025 | Impella |
| Novo Nordisk INC | $320.30 | 2024-2025 | Wegovy |
| Biogen, INC. | $252.14 | 2022-2024 | Tysabri, Vumerity, Avonex |
| Novartis Pharmaceuticals Corporation | $234.05 | 2023-2024 | |
| Amneal Pharmaceuticals LLC | $199.82 | 2023-2024 | Rytary |
| Neurelis, INC. | $164.37 | 2023-2024 | Valtoco |
| Argenx US, INC. | $159.76 | 2023 | Vyvgart, Vyvgart Hytrulo |
| Pfizer INC. | $150.64 | 2022-2024 | |
| Lilly USA, LLC | $139.24 | 2023-2024 | Amyvid |
| Boston Scientific Corporation | $134.18 | 2024-2025 | Watchman Flx, Bodyguardian, General - Pain Management |
| E.R. Squibb & Sons, L.L.C. | $129.70 | 2024 | Camzyos |
| Sumitomo Pharma America, INC. | $120.31 | 2023-2024 | Aptiom |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venus Kell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.